Answers are grounded in this paper and cite their sources.
Mucosal immunization of domestic animals provides protection against infection through respiratory, gastrointestinal, and ocular entry points, while triggering the development of immunity locally and systemically. However, its efficiency is hindered by biological barriers, such as antigen degradation, mucus clearance, limited epithelial permeability, insufficient uptake by antigen-presenting cells, and the mucosal immune system. This review considers mucosal nanodelivery technologies considering barriers and species awareness. It evaluates polymeric, lipid, protein, inorganic, and biomimetic nanocarriers; mucoadhesive and mucopenetrating strategies; M cell and dendritic cell targeting; stimuli responsive delivery; and nanoadjuvants. Such approaches may facilitate the protection, translocation, cellular uptake, and immunogenicity of antigens, but increased delivery or enhanced antibody titers do not mean protective efficacy. Species-specific characteristics of mucosal physiology and immunity are highlighted in poultry, porcine, ruminant, aquatic, and companion animals. Therefore, a formulation design that considers species and tissue specificity may be considered as a working hypothesis, although comparative studies are lacking. Potential difficulties in the further advancement of the field include formulation instability, repeatability, scale up, safety, environmental issues, regulations, costs, and the use of a variable animal model for efficacy evaluation.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: